AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab
Management noted that the trial was randomized, double-blind, and placebo-controlled. It met its primary and all secondary endpoints as patients showed significant improvement in their daily activities related to gMG at 26 weeks compared to placebo. gMG is a rare autoimmune disease that causes muscle weakness and loss of function. CEO of AstraZeneca PLC (NASDAQ:AZN) Rare Disease Marc Dunoyer noted that the results confirm gefurulimab's potential as a fast-acting and sustained treatment option. Management expects the treatment to become first-line with a good safety profile.
A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.
AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that focuses on oncology, rare diseases, cardiovascular, respiratory, immunology, and vaccines.
While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
FACT FOCUS: RFK Jr.'s reasons for cutting mRNA vaccine not supported by evidence
Although mRNA vaccines saved millions of lives during the COVID-19 pandemic, U.S. Health Secretary Robert F. Kennedy Jr. incorrectly argued they are ineffective to justify the Department of Health and Human Service's recent decision to cancel $500 million in government-funded research projects to develop new vaccines using the technology. The longtime vaccine critic said in an X video posted Tuesday evening that mRNA vaccines do not adequately prevent upper respiratory infections such as COVID-19 and the flu, advocating instead for the development vaccines that use other processes. COVID-19 is the only virus for which real-world data on mRNA vaccine effectiveness is currently available, as mRNA vaccines for other diseases, including the flu, are still under development. The two scientists whose discoveries enabled the creation of mRNA vaccines against COVID-19 won a Nobel Prize in 2023 for their work. Kennedy's claim ignores how mRNA vaccines work, according to experts. They prevent against severe infection and death, but cannot completely prevent an infection from occurring in the first place. Plus, years of research supports the effectiveness of COVID-19 vaccines that use mRNA technology. Here's a closer look at the facts. KENNEDY: 'As the pandemic showed us, mRNA vaccines don't perform well against viruses that infect the upper respiratory tract.' THE FACTS: His claim is contradicted by scientific evidence. Countless studies show that vaccinated individuals fare far better against COVID-19 infections than those who are unvaccinated, while others have estimated that COVID-19 vaccines prevented millions of deaths during the global pandemic. The mRNA vaccines do not prevent respiratory diseases entirely, experts say. Rather, they can prevent more serious illness that leads to complications and death. For example, an mRNA vaccine against COVID-19 may prevent an infection in the upper respiratory tract that feels like a bad cold from spreading to the lower respiratory tract, where it could affect one's ability to breathe. 'A vaccine cannot block a respiratory infection,' said Dr. Jake Scott, an infectious diseases physician and clinical associate professor at Stanford University School of Medicine. 'That's never been the standard for a respiratory virus vaccine. And it's never been the expectation, and it's never been that realistic.' He called Kennedy's claim 'misguided.' Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University, had a similar outlook. 'Vaccinations don't have to be neutralizing, meaning that you're not going to get COVID,' he said. 'But the important part of a vaccination is that they reduce hospitalization and death. And a reduction in hospitalization and death is proof of an effective vaccine.' Vaccines have traditionally required growing viruses or pieces of viruses called proteins and then purifying them. Then a small dose of the vaccine is injected to train the body how to recognize when a real infection hits so it's ready to fight back. But this method takes a long time. The mRNA technology speeds up the process and allows existing vaccines to be updated more quickly. The 'm' in mRNA stands for messenger because the vaccine carries instructions for our bodies to make proteins. Scientists figured out how to harness that natural process for vaccines by making mRNA in a lab. They take a snippet of the genetic code that carries instructions for making the protein they want the vaccine to target. Injecting that snippet instructs the body to become its own mini-vaccine factory, making enough copies of the protein for the immune system to recognize and react. Scott explained that mRNA vaccines are not a 'magic force field' that the immune system can use to block an infection, as it can't detect whether a virus is nearby. It can only respond to a virus that has already entered the body. In the case of COVID-19, this means that the virus could cause an upper respiratory tract infection — a cold, essentially — but would be significantly less likely to cause more severe consequences elsewhere. Myriad studies on the effectiveness of COVID-19 vaccines have been published since they first became available in late 2020. Although protection does wane over time, they provide the strongest barrier against severe infection and death. For example, a 2024 study by the World Health Organization found COVID-19 vaccines reduced deaths in the WHO's European region by at least 57%, saving more than 1.4 million lives since their introduction in December 2020. A 2022 study published in the journal Lancet Infectious Diseases found that nearly 20 million lives were saved by COVID-19 vaccines during their first year. Researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom. The main finding — that 19.8 million COVID-19 deaths were prevented — is based on estimates of how many more deaths than usual occurred during the time period. Using only reported COVID-19 deaths, the same model yielded 14.4 million deaths averted by vaccines. Another 2022 study, published in The New England Journal of Medicine, reported that two mRNA vaccines were more than 90% effective against COVID-19. Operation Warp Speed, the federal effort to facilitate the development and distribution of a COVID-19 vaccine, began under the first Trump administration. 'What I don't understand is why is President Trump is allowing RFK Jr. to undermine his legacy that led to a medical intervention that literally saved millions of lives?' Coller said. 'Why is Trump allowing RFK to undermine U.S. leadership in biomedical research and drug development?' ___ Find AP Fact Checks here: Solve the daily Crossword
Yahoo
13 minutes ago
- Yahoo
CF Industries misses quarterly profit estimates on higher costs; shares fall
(Reuters) -CF Industries missed estimates for second-quarter profit on Wednesday, as higher costs weighed on the fertilizer firm, sending its shares down 4.3% in extended trading. The company's quarterly cost of sales was up about 27% at $1.14 billion from a year earlier on higher natural gas costs, which were up 77% at $3.36 per million British thermal units. U.S. natural gas prices, a key feedstock for nitrogen fertilizers, rose in the second quarter as power demand spiked on the back of energy-hungry data centers, escalating production costs for fertilizer producers. The Northbrook, Illinois-based company reported an adjusted profit of $2.35 per share for the three months ended June 30, compared with the analysts' average estimate of $2.54, according to data compiled by LSEG. Crop prices — including those of soybean, wheat and corn — have been falling in recent quarters due to oversupply and weakening demand, forcing farmers to cut back spending on fertilizers, affecting companies such as CF Industries. Peer Mosaic also missed second-quarter profit estimates on Tuesday, as higher costs weighed against gains from stronger potash prices and robust sales in Brazil. CF Industries' quarterly net earnings attributable to common stockholders fell about 8% to $386 million from a year earlier. The results come at a time when the agrichemical industry is bracing itself for a potential fallout from U.S. President Donald Trump's sweeping tariffs on most imports, which are expected to lower demand and curb farmers' spending. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Rivian Stock Plunges After Brutal Q2 Earnings and Weak Outlook
Aug 6 - Rivian Automotive (NASDAQ:RIVN) dipped more than 3% on Wednesday after posting mixed Q2 results that left Wall Street unimpressed. The EV maker reported a loss of $0.97 per share, missing consensus expectations by $0.32, though revenue came in slightly ahead at $1.30 billion versus the expected $1.27 billion, a 12.5% year-over-year increase. Warning! GuruFocus has detected 5 Warning Signs with RIVN. The revenue beat didn't do much to soften the blow of the wider-than-expected loss, as investors responded with a sell-off that pushed shares down to $12.00 during mid-day trading. Adding to the market's hesitation, the company continues to burn cash aggressively, with negative margins and return on equity weighing heavily on investor sentiment. Analyst ratings remain mixed, with a wide price target range from $12 to $18 and a consensus near $14.30. Insider selling by Rivian's CEO and CFO in recent months also added downward pressure, even as institutional ownership remains strong. While Rivian's long-term vision in EVs and autonomous tech continues to attract attention, the company faces mounting challenges balancing growth and profitability in a capital-intensive space. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
